Corvus to manufacture armoured vehicle suspensions

Melbourne defence manufacturer Corvus Technology Solutions is preparing to transfer advanced defence technologies to Victoria to build the sophisticated suspension systems for the Army’s new Redback Infantry Fighting Vehicles. The company has opened a new office in Gyeonggi-do, South Korea to complete negotiations with Hanwha Defence Australia which will build the Redbacks at a new…

Hydrogen equipment manufacturer Hysata announces $172 million Series B round

Electrolyser manufacturer Hysata has completed a record-setting Series B funding round worth $US 111.3 million (approximately $172 million) and led by bp Ventures and Templewater. Hysata announced an oversubscribed $42.5 million Series A round in August 2022, with the Series B seeing investors such as Bluescope’s venture business, BluescopeX, Virescent Ventures, the IP Group and…

Towards 3% R&D – A national strategy to reverse innovation slide by Dr John Howard

A National Business Research and Development Strategy and Action Plan is the logical conclusion of our editorial series – Towards 3% R&D – Turbocharging Australia’s Innovation Effort. In this edited excerpt, Dr John Howard lays out the elements of the strategy. The full paper can be downloaded below. Australian business investment in R&D collapsed during…

Towards 3% R&D – Factory of the future by Philipp Dautel

Innovation hubs that allow companies to engage with researchers and test their systems on the latest equipment are seen as part of the answer to Australia’s faltering innovation system. Here, in our editorial series – Towards 3% R&D – Turbocharging Australia’s Innovation Effort – Philipp Dautel of one such hub the Factory of the Future…

Victoria backs IDT Australia to make anti-cancer drugs

The Victorian government has announced backing for pharmaceutical manufacturer IDT Australia to boost production of live-saving cancer treatments. IDT Australia will build a new facility in Boronia, Melbourne to manufacture Antibody Drug Conjugates (ADCs) which have the specificity of monoclonal antibodies and deliver chemotherapy agents to cancer tumor sites. ADCs are set to replace almost…